Leica Developing CDx to Screen Patients for Galena Breast Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Galena Biopharma and Leica Biosystems today announced a deal for the development of a companion diagnostic for Galena's therapeutic for breast cancer.

Under the partnership, Leica's Bond Oracle HER2 IHC System companion diagnostic will be used to select patients for Galena's NeuVax Phase 3 Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment, or PRESENT, study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.